GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (...
Saved in:
Main Authors: | Roberto De Masi (Author), Stefania Orlando (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification and Validation of IFI44 as a Novel Biomarker for Primary Sjögren’s Syndrome
by: Wei B, et al.
Published: (2024) -
The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021) -
Molecular biomarkers in multiple sclerosis
by: Michaličková Danica, et al.
Published: (2022) -
Proteomic Techniques as Biomarkers for Multiple Sclerosis
by: J Gordon Millichap
Published: (2012) -
Interferon (IFN)-Induced Protein 35 (IFI35), a Type I Interferon-Dependent Transcript, Upregulates Inflammatory Signaling Pathways by Activating Toll-Like Receptor 3 in Human Mesangial Cells
by: Tadaatsu Imaizumi, et al.
Published: (2016)